← 홈

전체 프로그램

ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 4,162개
ADCSFDAFDABiologicFundación Pública Andaluza para…Deruxtecan-Dlnk Quantificat…Phase 3

Datopotamab deruxtecan (Datopotamab deruxtecan)

Breast Cancer; Metastatic Breast Cancer · Lung Cancer

#LungCancer#ADC#Phase3#FDA승인#항체약물접합체+5
효능 ORR 79%임상시험 44상태 RECRUITING
CGTAAVAHOTFDACuratedFDABiologicNovartisSMN1 cDNA under hybrid CMV …Approved

onasemnogene abeparvovec (Zolgensma, AVXS-101, onasemnogene abeparvovec-xioi)

Spinal muscular atrophy (SMA) Type 1–3, pediatric · SMN1 (AAV9)

#SMN1AAV9#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 26상태 APPROVED
ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4
효능 ORR 71.7%임상시험 23상태 RECRUITING
CGTAAVBHOTFDACuratedFDABiologicSarepta TherapeuticsMicro-dystrophin cassetteApproved

delandistrogene moxeparvovec (Elevidys, SRP-9001, delandistrogene moxeparvovec-rokl)

Duchenne muscular dystrophy (DMD) — ambulatory / label-expanded populations · Micro-dystrophin (AAVrh74)

#Micro-dystrophinAAVrh74#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 12상태 APPROVED
ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3
효능 ORR 33.3%임상시험 12상태 RECRUITING
CGTSHOTFDACuratedFDABiologicFerring PharmaceuticalsHuman interferon alfa-2bApproved

nadofaragene firadenovec (Adstiladrin, rAd-IFNα/Syn3, nadofaragene firadenovec-vncg)

High-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) · IFNα2b (adenoviral)

#IFN2badenoviral#CGT#Approved#FDA승인#바이오모아추천+5
효능 ORR 55%임상시험 10상태 APPROVED
CGTBHOTFDACuratedFDABiologicVertexApproved

exagamglogene autotemcel (Casgevy, exa-cel, CTX001)

Sickle cell disease with recurrent VOCs; transfusion-dependent β-thalassemia · BCL11A enhancer (CRISPR/Cas9) → HbF

#BCL11AenhancerCRISPRCas9HbF#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 9상태 APPROVED
CGTAAVBHOTFDACuratedFDABiologicBioMarinB-domain deleted FVIIIApproved

valoctocogene roxaparvovec (Roctavian, BMN 270, valoctocogene roxaparvovec-rvox)

Severe hemophilia A in adults · Factor VIII (AAV5)

#FactorVIIIAAV5#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 8상태 APPROVED
CGTAAVBHOTFDACuratedFDABiologicCSL BehringFactor IX Padua variant (hy…Approved

etranacogene dezaparvovec (Hemgenix, AMT-061, CSL222, etranacogene dezaparvovec-drlb)

Hemophilia B (congenital Factor IX deficiency) in adults · Factor IX (AAV5 Padua)

#FactorIXAAV5Padua#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 7상태 APPROVED
CGTAAVBHOTFDACuratedFDABiologicSpark TherapeuticsHuman RPE65 cDNAApproved

voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl)

Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations · RPE65 (AAV2)

#RPE65AAV2#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 7상태 APPROVED
CGTCHOTFDACuratedFDABiologicbluebird bioβA-T87Q-globinApproved

lovotibeglogene autotemcel (Lyfgenia, lovo-cel, bb1111)

Sickle cell disease with recurrent vaso-occlusive events · βA-T87Q-globin (lentiviral)

#A-T87Q-globinlentiviral#CGT#Approved#FDA승인#바이오모아추천+5
임상시험 2상태 APPROVED
ADCCFDAFDABiologicstaleAstellasPhase 3

enfortumab vedotin (Padcev, Enfortumab Vedotin-Ejfv)

Advanced or Metastatic Solid Malignancies · Advanced or Metastatic Solid Malignancie

#AdvancedorMetastaticSolidMaligna#ADC#Phase3#FDA승인#항체약물접합체+2
임상시험 1상태 ACTIVE
ADCCFDAFDABiologicstaleRochePreclinical

Polatuzumab Vedotin-Piiq (Polatuzumab Vedotin-Piiq)

Diffuse Large B-Cell Lymphoma (DLBCL) · Diffuse Large B-Cell Lymphoma (DLBCL)

#DiffuseLargeB-CellLymphomaDLBCL#ADC#Preclinical#FDA승인#항체약물접합체+2
임상시험 1상태 ACTIVE
ADCCFDAFDABiologicFDA approved (openFDA)Approved

DATOPOTAMAB DERUXTECAN-DLNK (DATOPOTAMAB DERUXTECAN-DLNK)

FDA-approved indication · See label

#Seelabel#ADC#Approved#FDA승인#항체약물접합체+3
임상시험 0상태 APPROVED
ADCCFDAFDABiologicFDA approved (openFDA)Approved

TELISOTUZUMAB VEDOTIN-TLLV (TELISOTUZUMAB VEDOTIN-TLLV)

FDA-approved indication · See label

#Seelabel#ADC#Approved#FDA승인#항체약물접합체+3
임상시험 0상태 APPROVED
AntibodyHotRocheatApproved

Bevacizumab (Bevacizumab)

Colorectal Neoplasms · Recurrent Platinum-Sensitive Fallopian T

#RecurrentPlatinum-SensitiveFallo#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1131상태 RECRUITING
AntibodyHotRochevedotin, rituximab, cycloph…Approved

rituximab (rituximab)

Rheumatic Disease · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 1091상태 DISCONTINUED
AntibodyHotEli LillyreleaseApproved

Cetuximab (Cetuximab)

Locally Recurrent Skin Squamous Cell Carcinoma; Metastatic Skin Squamous Cell Carcinoma · Head and Neck Cancer

#HeadandNeckCancer#Antibody#Approved#인기#항체+5
효능 ORR 100%임상시험 757상태 RECRUITING
AntibodyHotRochederuxtecan (Dato-DXd, Datro…Approved

trastuzumab (Herceptin)

Non Small Cell Lung Cancer; Colorectal Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#Antibody#Approved#인기#항체+5
효능 ORR 91.8%임상시험 676상태 RECRUITING
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 648상태 RECRUITING

2 / 209 페이지

← 이전다음 →